门诊经环甲膜入路羟基磷灰石钙注射喉成形术的安全性
回顾性分析单中心2007至2016年617例患者共955例次门诊经环甲膜入路羟基磷灰石钙(CaHA)注射喉成形术,失败率0.5%,需积极干预的失败与主要并发症发生率为1.6%,作者认为该入路与常规经口注射喉成形术同样安全。
要点
- 失败5例(0.5%),需积极干预的失败与主要并发症合计发生率1.6%。
- 术中并发症为浅表注射8例(0.8%)。
- 急性与迟发性呼吸困难分别为3例(0.3%)和2例(0.2%)。
核心结论
- 作者认为门诊经环甲膜入路CaHA注射喉成形术与常规经口注射喉成形术同样安全。
研究设计与样本
- 单中心2007至2016年共实施962例次门诊经环甲膜入路CaHA注射喉成形术,由同一位医生完成;纳入617例患者的955例次操作,回顾性查阅病历。
- 并发症按发生时间分类:术中发生者为术中并发症,注射后1周内发生者为急性并发症,1周后发生且病历记录超过两次者为迟发并发症,失败病例单独归类。
主要发现
- 失败5例(0.5%);术中浅表注射8例(0.8%);急性呼吸困难3例(0.3%),迟发性呼吸困难2例(0.2%)。
- 需积极干预的失败与主要并发症发生率为1.6%。
关键数值与推荐
- 原文未报告
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the safety of office-based calcium hydroxylapatite (CaHA) injection laryngoplasty via the cricothyroid approach through an analysis of all procedures performed over a period of 10 years at a single institution. METHODS: In total, 962 office-based CaHA injection laryngoplasty via the cricothyroid approach procedures were performed by a single physician at our institution between 2007 and 2016. From these, 955 procedures performed in 617 patients were included in our analysis. The medical records of all 617 patients were retrospectively reviewed. We classified all procedure-related complications according to the time of onset. Complications that occurred during the procedure were considered intraprocedural complications, whereas complications that developed within 1 week after injection and those that developed after 1 week and were recorded more than twice in the medical records were considered acute and delayed complications, respectively. Failed cases were categorized separately as failure. RESULTS: Five cases were failed (0.5%). Intraprocedural complications included superficial injection in eight cases (0.8%). Acute and delayed onset of dyspnea was observed in three (0.3%) and two (0.2%) cases, respectively. The incidence of failures and major complications requiring active intervention was 1.6%. CONCLUSION: Our findings suggest that office-based CaHA injection laryngoplasty via the cricothyroid approach is as safe as conventional transoral injection laryngoplasty. LEVEL OF EVIDENCE: 4 Laryngoscope, 129:2361-2365, 2019.
引用
- Lee M, Lee DY, Kwon TK, et al. Safety of office-based percutaneous injection laryngoplasty with calcium hydroxylapatite. Laryngoscope. 2019. PMID: 30756397. doi:10.1002/lary.27861
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。